US-based Maxor Specialty Pharmacy, a VytlOne company, and a pharmacy solutions partner, announced on Wednesday that it has been selected by New Jersey-based biotech company Insmed to be a limited distribution provider of Brinsupri.
Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and paediatric patients 12 years of age and older.
The company said brinsupri is the latest addition to a growing number of limited distribution products available through VytlOne.
"We are excited to partner with Insmed for the launch of Brinsupri, the first FDA-approved medication for the treatment of bronchiectasis," said Joel Wright, president, VytlOne Pharmacy Services. "This milestone underscores our commitment to the rare disease community, and we are honoured to play a role in the improvement of the lives of our bronchiectasis patients."
Destiny Pharma launches research on XF-73 for cystic fibrosis MRSA infections
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence